

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/646,682
Filing Date	08/22/2003
First Named Inventor	Dennis S. Fernandez
Art Unit	1631
Examiner Name	Eric S. DeJong
Attorney Docket Number	FERN-P013

Sheet 1 of 2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	GENSET. "The Science of Drug Response Genes." Business Opportunities, Pharmacogenomics. April 2002 (online). Retrieved from the Internet:	
		<URL: http://www.genxy.com/Business/bus_pharmaco.html >.	
	2	WEBER, WENDELL, "The Legacy of Pharmacogenetics and potential Applications", (2001), pages 1-18, Volume 479, Elsevier	
	3	SCHOENEBERG, T. et al., "Mutant G-protein-coupled receptors as a cause of human diseases", Pharmacology & Therapeutics, 2004,	
		pp 173-206, VOL. 104, Elsevier, Amsterdam/The Netherlands.	
	4	OETTING, W. S. et al., "Linkage Analysis with Multiplexed Short Tandem Repeat Polymorphisms Using Infrared Fluorescence and M13 Tailed Primers", Genomics, 1995,	
		Vol. 30, pp. 450-458, Elsevier, Amsterdam/The Netherlands.	
	5	WOOD, A., "Racial Differences in the Response to Drugs - Pointers to Genetic Differences", New England Journal of Medicine, May 3, 2001,	
		pp 1393-1396, Vol. 344, No 18, Massachusetts Medical Society, Waltham, Mass/US	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.